IL124620A0 - Chromosome 13-linked breast cancer susceptibility gene - Google Patents

Chromosome 13-linked breast cancer susceptibility gene

Info

Publication number
IL124620A0
IL124620A0 IL12462096A IL12462096A IL124620A0 IL 124620 A0 IL124620 A0 IL 124620A0 IL 12462096 A IL12462096 A IL 12462096A IL 12462096 A IL12462096 A IL 12462096A IL 124620 A0 IL124620 A0 IL 124620A0
Authority
IL
Israel
Prior art keywords
breast cancer
relates
gene
human
brca2
Prior art date
Application number
IL12462096A
Other languages
English (en)
Original Assignee
Myriad Genetics Inc
Univ Pennsylvania
Hsc Res Dev Lp
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124620(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/639,501 external-priority patent/US5837492A/en
Application filed by Myriad Genetics Inc, Univ Pennsylvania, Hsc Res Dev Lp, Endorecherche Inc filed Critical Myriad Genetics Inc
Publication of IL124620A0 publication Critical patent/IL124620A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL12462096A 1995-12-18 1996-12-17 Chromosome 13-linked breast cancer susceptibility gene IL124620A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57377995A 1995-12-18 1995-12-18
US57535995A 1995-12-20 1995-12-20
US57655995A 1995-12-21 1995-12-21
US58539196A 1996-01-11 1996-01-11
US08/639,501 US5837492A (en) 1995-12-18 1996-04-29 Chromosome 13-linked breast cancer susceptibility gene
PCT/US1996/019598 WO1997022689A1 (fr) 1995-12-18 1996-12-17 Gene de predisposition au cancer du sein lie au chromosome 13

Publications (1)

Publication Number Publication Date
IL124620A0 true IL124620A0 (en) 1998-12-06

Family

ID=27541925

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12462096A IL124620A0 (en) 1995-12-18 1996-12-17 Chromosome 13-linked breast cancer susceptibility gene

Country Status (11)

Country Link
US (2) US6124104A (fr)
EP (1) EP0785216B2 (fr)
JP (1) JP3455228B2 (fr)
AT (1) ATE230759T1 (fr)
AU (1) AU1461597A (fr)
CA (1) CA2239733C (fr)
DE (1) DE69625678T3 (fr)
IL (1) IL124620A0 (fr)
NO (1) NO982785L (fr)
NZ (1) NZ326525A (fr)
WO (1) WO1997022689A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
EP1012577A4 (fr) * 1996-12-03 2004-08-04 Michael R Swift Predisposition au cancer du sein liee a des mutations affectant le locus du gene d'ataxie telangiectasie
GB9708221D0 (en) * 1997-04-23 1997-06-11 Cancer Res Campaign Tech Substances and uses thereof
IL134505A0 (en) * 1997-08-15 2001-04-30 Oncormed Inc Coding sequence haplotypes of the human brca2 gene
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6051379A (en) * 1997-09-23 2000-04-18 Oncormed, Inc. Cancer susceptibility mutations of BRCA2
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US7148016B1 (en) * 1999-01-14 2006-12-12 Ca*Tx Inc. Immunoassays to detect diseases or disease susceptibility traits
AUPQ421699A0 (en) * 1999-11-24 1999-12-16 University Of Western Australia, The Tumour suppressor factor
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
JP2004536555A (ja) 2000-11-03 2004-12-09 ダナ ファーバー キャンサー インスティテュート 癌感受性の診断のための方法及び組成物並びに欠損ｄｎａ修復メカニズム及びその処置
US6816789B2 (en) * 2001-04-19 2004-11-09 Varian, Inc. Method and system for analyzing chromatograms
NZ545283A (en) * 2001-06-05 2008-01-31 Auckland Uniservices Ltd Methods and compositions for determining a subject's predisposition to developing impaired lung function
WO2003044212A2 (fr) * 2001-11-16 2003-05-30 Exelixis, Inc. Acides nucleiques et polypeptides de brca2 d'invertebre et procedes d'utilisation associes
AU2002351177A1 (en) * 2001-11-29 2003-06-10 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
EP1896607A4 (fr) * 2005-05-10 2009-12-16 Synergenz Bioscience Ltd Procédés et compositions pour l'évaluation de la fonction et de troubles pulmonaires
EP1888776A4 (fr) * 2005-05-19 2009-07-29 Synergenz Bioscience Ltd Méthodes et compositions pour évaluation de la fonction et de troubles pulmonaires
US8076065B2 (en) * 2005-05-19 2011-12-13 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
WO2006123943A1 (fr) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methodes d'analyse de polymorphismes et leurs utilisations
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN101449162B (zh) 2006-05-18 2013-07-31 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
WO2007148997A1 (fr) * 2006-06-22 2007-12-27 Pomorska Akademia Medyczna Détermination de la prédisposition au cancer par l'identification de combinaisons génotypiques de variants spécifiques des gènes cyp1b1, brca2 et chek2
AU2007284649B2 (en) * 2006-08-11 2013-09-26 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
US7993835B1 (en) 2007-05-11 2011-08-09 Myriad Genetics, Inc. BRCA2 mutations and use thereof
WO2010045318A2 (fr) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
EP3181705A1 (fr) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Procédés et systèmes permettant d'utiliser des exosomes pour déterminer des phénotypes
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US20130018700A1 (en) * 2011-07-14 2013-01-17 International Business Machines Corporation Optimizing product portfolios under customer choice
US20140222512A1 (en) * 2013-02-01 2014-08-07 Goodsnitch, Inc. Receiving, tracking and analyzing business intelligence data
US20140343982A1 (en) * 2013-05-14 2014-11-20 Landmark Graphics Corporation Methods and systems related to workflow mentoring
AU2015236054B2 (en) * 2014-03-25 2019-11-21 Five3 Genomics, Llc Systems and methods for RNA analysis in functional confirmation of cancer mutations
US10133996B2 (en) * 2014-04-22 2018-11-20 International Business Machines Corporation Object lifecycle analysis tool
CN110714079A (zh) * 2015-06-02 2020-01-21 南京医科大学 一种用于乳腺癌辅助诊断的突变基因及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (fr) 1981-08-31 1985-06-04 Jerry L. Gregory Appareil de fermentation en continue contenant un microorganisme immobilise
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5773278A (en) † 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1995015334A1 (fr) * 1993-11-30 1995-06-08 California Pacific Medical Center Research Institute SONDE D'ADNc UTILE DANS LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DU SEIN
WO1995019369A1 (fr) * 1994-01-14 1995-07-20 Vanderbilt University Procede de detection et de traitement du cancer du sein
CA2238010A1 (fr) * 1995-11-23 1997-05-29 Cancer Research Campaign Technology Limited Materiaux et procedes relatifs a l'identification et au sequencage du gene de susceptibilite brca2 du cancer et ses utilisations
GB2307477B (en) * 1995-11-23 1997-10-22 Cancer Res Campaign Tech Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US5879890A (en) † 1997-01-31 1999-03-09 The Johns Hopkins University APC mutation associated with familial colorectal cancer in Ashkenazi jews
CA2289109A1 (fr) † 1997-04-30 1998-11-05 Genzyme Limited Syndrome de type 1 consecutif a une deficience glucidique de la glycoproteine
EP0983389A1 (fr) † 1997-06-04 2000-03-08 Rijksuniversiteit te Leiden Trousse de controle diagnostique servant a determiner une predisposition au cancer du sein et des ovaires, materiaux et procedes servant a effectuer cette determination
US6376176B1 (en) † 1999-09-13 2002-04-23 Cedars-Sinai Medical Center Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease
MXPA02008967A (es) † 2000-03-16 2003-02-12 Sucampo Ag Tratamiento de hipertension ocular y glaucoma.
EP1280814A4 (fr) † 2000-04-13 2003-05-14 Genaissance Pharmaceuticals Association d'haplotypes du recepteur adrenergique beta2 reagissant aux medicaments
US20060105403A1 (en) † 2001-06-13 2006-05-18 Venezia Nicole D Braca1/acc alpha molecular complexes, diagnostic and therapeutic applications

Also Published As

Publication number Publication date
US6124104A (en) 2000-09-26
CA2239733A1 (fr) 1997-06-26
US6033857A (en) 2000-03-07
WO1997022689A1 (fr) 1997-06-26
DE69625678T3 (de) 2006-11-09
EP0785216B2 (fr) 2006-06-07
DE69625678T2 (de) 2003-11-06
ATE230759T1 (de) 2003-01-15
AU1461597A (en) 1997-07-14
CA2239733C (fr) 2001-04-03
DE69625678D1 (de) 2003-02-13
EP0785216A1 (fr) 1997-07-23
NO982785D0 (no) 1998-06-17
EP0785216B1 (fr) 2003-01-08
NZ326525A (en) 1999-11-29
NO982785L (no) 1998-08-17
JP3455228B2 (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
IL124620A0 (en) Chromosome 13-linked breast cancer susceptibility gene
EP1260520A3 (fr) Gène BRCA2 impliqué dans la susceptibilité au cancer du sein , du chromosome 13,
MX9701075A (es) Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
CA2196795A1 (fr) Procede pour diagnostiquer une predisposition au cancer du sein et des ovaires
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO2001085911A3 (fr) Gene de sensibilite au cancer de la prostate lie au chromosome 17p et paralogue et genes orthologues